nir178
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 28, 2017 (NCT03207867)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 1
- Head and Neck Neoplasms · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Melanoma · Phase 2
- Neoplasms · Early Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
Mechanism of action
- Alpha-2a adrenergic receptorANTAGONIST
ADRA2A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04895748 | Phase 1 | Nov 18, 2021 | Novartis |
| NCT04237649 | Early Phase 1 (Phase 1) | Feb 28, 2020 | Novartis |
| NCT03742349 | Phase 1 | Jan 31, 2019 | Novartis |
| NCT03549000 | Phase 1 | Jul 18, 2018 | Novartis |
| NCT03207867 | Phase 2 | Aug 28, 2017 | Novartis |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 5 | 5 | 2 | 2017 |
1 organizations
Page 1 / 1